Cesca Therapeutics (NASDAQ:KOOL) and Misonix (NASDAQ:MSON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Cesca Therapeutics and Misonix, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cesca Therapeutics 0 0 1 0 3.00
Misonix 0 0 2 0 3.00

Cesca Therapeutics currently has a consensus target price of $1.50, suggesting a potential upside of 328.57%. Misonix has a consensus target price of $26.00, suggesting a potential upside of 41.07%. Given Cesca Therapeutics’ higher possible upside, equities analysts clearly believe Cesca Therapeutics is more favorable than Misonix.

Volatility & Risk

Cesca Therapeutics has a beta of -0.96, meaning that its share price is 196% less volatile than the S&P 500. Comparatively, Misonix has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cesca Therapeutics and Misonix’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cesca Therapeutics $14.52 million 0.52 -$21.22 million ($0.98) -0.36
Misonix $36.68 million 4.74 -$7.61 million N/A N/A

Misonix has higher revenue and earnings than Cesca Therapeutics.

Institutional & Insider Ownership

3.1% of Cesca Therapeutics shares are owned by institutional investors. Comparatively, 12.9% of Misonix shares are owned by institutional investors. 15.7% of Cesca Therapeutics shares are owned by company insiders. Comparatively, 23.8% of Misonix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cesca Therapeutics and Misonix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cesca Therapeutics -322.75% -18.05% -10.84%
Misonix -20.75% -7.91% -6.69%

Summary

Misonix beats Cesca Therapeutics on 10 of the 11 factors compared between the two stocks.

About Cesca Therapeutics

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

About Misonix

Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. Its products include the bonescalpel cutting system, which is used for surgical procedures of the spine and on maxillofacial procedures; the sonastar surgical aspirator, which is used to emulsify and remove soft and hard tumors; the sonicone wound cleansing and debridement system, which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. The company’s ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. The company was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.